PROCTER & GAMBLE HEALTH
|
|
| BOM : 500126     NSE : PGHL     | |
| LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : None or < 25% |
Mar 18,2026 |
|
Price(EOD): ₹ 4,936.65
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 8,194.84 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| PROCTER & GAMBLE HEALTH | 0.7% | -1% | -7.1% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.6% | 5.7% | 7.7% |
| DIVIS LABORATORIES | -4.2% | -1.4% | 9.6% |
| CIPLA | -3.6% | -3.7% | -10.2% |
| TORRENT PHARMACEUTICALS | -2.8% | 5.7% | 39.3% |
| DR REDDYS LABORATORIES | -3.2% | 1.2% | 14.2% |
| MANKIND PHARMA | -7.9% | 0.4% | -5.4% |
| ZYDUS LIFESCIENCES | -3.5% | -1.7% | -1.5% |
| LUPIN | -2% | 4.5% | 15.9% |
FUNDAMENTAL ANALYSIS OF PROCTER & GAMBLE HEALTH
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF PROCTER & GAMBLE HEALTH
 | Ratio | Standalone | |
|---|---|---|
|
P/E P/B P/S |
27.92
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 293.49 Cr
[Latest Qtr - Dec2025 - Standalone Results ] 15.4
P/B Calculated based on Book Value of Rs 532.07 Cr
[Latest Year - Mar2025 - Standalone Results ] 6.08
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2025 - Standalone Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
10% 23% -7% |
SHARE PRICE MOMENTUM OF PROCTER & GAMBLE HEALTH
PROCTER & GAMBLE HEALTH vs SENSEX
DEBT OF PROCTER & GAMBLE HEALTH
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2025 2024 2023 Avg_3yrs |
0 0 0 - |
- - - - |
|
[Last Annual Data : Mar2025]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF PROCTER & GAMBLE HEALTH
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Dec2025 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF PROCTER & GAMBLE HEALTH
| Standalone | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
15.06% -8.16% -8.57% -12.37% |
20.69% -10.51% -10.58% -14.64% |
| QtrlyTrend |
-4 | |
| Latest Qtr: Dec2025 | ||
| Quarterly Result Analysis → | ||
PROCTER & GAMBLE HEALTH related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE HEALTHCARE | -2.8% | 0.2% | 8.6% |
| BSE SMALLCAP | -5.8% | -8.9% | -10.5% |
You may also like the below Video Courses
FAQ about PROCTER & GAMBLE HEALTH
Is PROCTER & GAMBLE HEALTH good for long term investment?
As on Mar 18,2026, the Fundamentals of PROCTER & GAMBLE HEALTH look Strong and hence it may be good for long term investment! See Financial Performance of PROCTER & GAMBLE HEALTH . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is PROCTER & GAMBLE HEALTH UnderValued or OverValued?
As on Mar 18,2026, PROCTER & GAMBLE HEALTH is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of PROCTER & GAMBLE HEALTH ?
As on Mar 18,2026, the Intrinsic Value of PROCTER & GAMBLE HEALTH is Rs. 4,488.74 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 4,488.74
Fair Value [Median EV / Sales Model] : Rs. 4,029.61
Fair Value [Median Price / Sales Model] : Rs. 5,279.89
Estimated Median Fair Value of PROCTER & GAMBLE HEALTH : Rs. 4,488.74
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.